Elsevier

The Lancet

Volume 377, Issue 9766, 19–25 February 2011, Page 635
The Lancet

Correspondence
Paricalcitol for reduction of albuminuria in diabetes

https://doi.org/10.1016/S0140-6736(11)60223-7Get rights and content

Cited by (7)

  • Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease

    2015, Journal of Diabetes and its Complications
    Citation Excerpt :

    The lack of statistical significance may also be due to the fact the subjects were in the late stage of disease. Nevertheless, there are other reports of microalbuminuria reduction with this drug in patients with less severe kidney disease (Ortiz et al., 2011). Another limitation of the study is that it is not known if the dose of paricalcitol used was sufficient.

  • Anorexia nervosa and the kidney

    2012, American Journal of Kidney Diseases
    Citation Excerpt :

    However, in patients with AN, urinary creatinine excretion might be very low compared with patients without AN. In theory, this low value could result in abnormally high levels of normalized proteinuria, and notably, the overall validity of spot protein-creatinine ratios have not been assessed in the context of AN.46 Using creatinine-based equations to estimate GFR may be misleading in many patients with AN.

View all citing articles on Scopus
View full text